Uterine leiomyomata in relation to insulin-like growth factor-i, insulin, and diabetes

Epidemiology

Volumn 20, Issue 4, 2009, Pages 604-610

  Baird, Donna D ^a,c   Travlos, Greg ^b   Wilson, Ralph ^b   Dunson, David B ^c   Hill, Michael C ^d   DAloisio, Aimee A ^a   London, Stephanie J ^a   Schectman, Joel M ^e  

^a Epidemiology Branch   (United States)

^b Clinical Pathology Group   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CAUCASIAN; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NEGRO; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; TUMOR VOLUME; UTERUS MYOMA;

ADULT; CELL PROLIFERATION; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LEIOMYOMA; LOGISTIC MODELS; MIDDLE AGED; UTERUS;

EID: 67651064746     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31819d8d3f     Document Type: Article

References (42)

1. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol. 2002;99:229-234.
2. Myers ER, Barber MW, Couchman GM, et al. Management of uterine fibroids (Evidence Report/Technology Assessment No. 34, contract 29097-0014 to the Duke Evidence-based Practice Center). Rockville, MD: Agency for Healthcare Research and Quality; July, 2001. AHRQ Publication 01-E052.
3. Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chro-mosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest. 1995;40:204-208.
4. Ross RK, Pike M, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986;293:359-362.
5. Schwartz SM, Marshall LM. Uterine leiomyomata. In: Goldman MB, Hatch MC, eds. Women and Health. San Diego, CA: Academic Press; 2000.
6. Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D. Estrogen-induced
7. changes in IGF-I, Myb family, and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. MolHum Reprod. 2005;11:441-450.
8. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
9. Boehm KD, Dalmon M, Gorodeski IG, Sheean LA, Utean WH, Ilan J. Expression ofthe insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev. 1990;27:93-101.
10. Vollenhoven BJ, Herington AC, Healy DL. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab. 1993;76: 1106 -1110.
11. Giudice LC, Irwin JC, Dsupin BA, et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IFGBP synthesis in human uterine leiomyomata. Hum Reprod. 1993;8:1796-1806.
12. Van Der Ven LT, Roholl PJ, Gloudemans T, et al. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer. 1997;75:1631-1640.
13. Englund K, Lindblom B, Carlstrom K, Gustavsson I, Sjoblom P, Blanck A. Gene expression and tissue concentrations of IGF-I in human myo-metrium and fibroids under different hormonal conditions. Mol Hum Reprod. 2000;6:915-920.
14. Wolanska M, Bankowski E. An accumulation of insulin-like growth factor I (IGF-I) in human myometrium and uterine leiomyomas in various stages of tumor growth. Eur Cytokine Netw. 2004;15:359-363.
15. Kim DI, Lee TK, Lim IS, Kim H, Lee YC, Kim CH. Regulation of IGF-I production and proliferation of human leiomyomal smooth muscle cells by Scutellaria barbata D. Don in vitro: isolation of flavanoids of apigenin and luteolin as acting compounds. Toxicol Appl Pharmacol. 2005;205: 213-224.
16. Wei JJ, Chiriboga L, Mittal K. Expression profile of the tumorigenic factors associated with tumor size and sex steroid hormone status in uterine leiomyomata. Fertil Steril. 2005;84:474-484.
17. Wei J, Chiriboga L, Mizuguchi M, Yee H, Mittal K. Expression profile of tuberin and some potential tumorigenic factors in 60 patients with uterine leiomyomata. Mod Pathol. 2005;18:179-188.
18. Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000;108(S5):795-802.
19. Burroughs KD, Howe SR, Okubo Y, et al. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol. 2002;172:83-93.
20. Van Der Ven LT, Gloudemans T, Roholl PJ, et al. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I. Int J Cancer. 1994;59:427-434.
21. Strawn EYJr, Novy MJ, Burry KA, Bethea CL. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am JObstet Gynecol. 1995;172:1837-1844.
22. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: 8 years on. Endocr Relat Cancer. 2006;13:273-278.
23. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:763-768.
24. Dawood MY, Khan-Dawood FS. Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril. 1994;61:617-621.
25. Huang J, Zou J, Xu B, Zhang Y, Chen X, Lier D. Affect of insulin-like growth factor I and estradiol on the growth ofuterine leiomyoma. Hunan Yi Ke Da Xue Xue Bao. 1999;24:29-32.
26. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. EndocrRev. 1997;18:801-831.
27. Van Der Ven LT, Van Buul-Offers SC, Gloudemans T, et al. Modulation of insulin-like growth factor (IGF) action by IGF-binding proteins in normal, benign, and malignant smooth muscle tissues. JClin Endocrinol Metab. 1996;81:3629-3635.
28. Faerstein E. Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol. 2001;153:11-19.
29. Siddle K, Urso B. Niesler CA, et al. Specificity in ligand binding and intracellular signaling by insulin and insulin-like growth factor receptors. Biochem Soc Trans. 2001;29:513-525.
30. Cramer SF, Robertson ALJr, Ziats NP, Pearson OH. Growth potential of human uterine leiomyomas: some in vitro observations and their implications. Obstet Gynecol. 1985;66:36-41.
31. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev. 1987;8:132-141.
32. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High incidence of uterine leiomyoma: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100-107.
33. Dunson DB, Baird DD. Bayesian modeling of incidence and progression of disease from cross-sectional data. Biometrics. 2002;58:813-822.
34. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. Physical activity is associated with reduced uterine leiomyoma incidence. Am J Epidemiol. 2007;165:157-163.
35. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am JEpidemiol. 2005;162:199-200.
36. Wise LA, Palmer JR, Stewart EA, Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril. 2007;87:1108 -1115.
37. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 2002;63:317-332.
38. Lacey JV, Potischman N, Madigan MP, et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a US case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:607-612.
39. Gomez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol. 2006;7:125-132.
40. Pittenger GL, Malik RA, Burcus N, Boulton AJ, Vinik AI. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotox-icity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care. 1999;22:1839-1844.
41. Missmer SA, Speigelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev. 2006;15:972-978.
42. Eckfeldt JH, Chambless LE, Shen YL. Short-term within-person variability in clinical chemistry test results. Experience from the atherosclerosis risk in communities study. Arch Pathol Lab Med. 1994;118:496-500.